Par Pharmaceutical, a prominent operating company of Endo International plc, is engaged in the development, manufacturing, and marketing of a broad portfolio of high-quality generic and specialty branded pharmaceuticals. Originally founded in 1978, Par established a strong reputation for producing affordable medicines, particularly in difficult-to-manufacture product categories. In 2015, Par Pharmaceutical was acquired by Endo International, a move that significantly expanded Endo's generics segment and capabilities, especially in controlled substances, injectables, and modified-release oral solids. Today, the Par brand continues to represent a significant portion of Endo's generic offerings, focusing on providing value to the healthcare system by increasing access to essential medications.
Serves as the main U.S. operational hub for Endo International, overseeing strategic, commercial, R&D coordination, and administrative functions for its various businesses, including the Par Pharmaceutical product lines.
The Malvern campus is a modern corporate facility designed to support a collaborative work environment for pharmaceutical innovation and operations. It houses key decision-makers and functional teams for Endo's U.S. business.
The work culture, reflecting Endo's broader corporate values, emphasizes quality, integrity, and a patient-centric approach. There's a focus on innovation in pharmaceutical development and operational excellence within a highly regulated industry.
This location is central to Endo's operations in the United States, its largest market. It plays a critical role in managing the development, manufacturing oversight, and commercialization of products under the Par Pharmaceutical brand and other Endo segments.
Through its parent company Endo International, Par Pharmaceutical's products and operations are part of a global network. Endo has a primary commercial focus in the U.S. market, supported by manufacturing facilities in the U.S. and India, and R&D centers in both countries. Global functions include research and development, API sourcing, finished product manufacturing, quality control and assurance, regulatory affairs, and supply chain management, ensuring the availability of its pharmaceuticals worldwide where approved.
1400 Atwater Dr
Malvern
Pennsylvania
USA
Address: One Ram Ridge Road, Chestnut Ridge, NY 10977, USA
Major site for manufacturing and distributing generic pharmaceuticals for the U.S. market, with specialized capabilities.
Address: 19270 Mccollough, Irvine, CA 92612, USA (Example, verify exact Endo sterile facility address)
Provides specialized manufacturing capabilities for sterile injectable drugs, serving hospitals and clinics primarily in North America.
Address: Plot No. SP-DSG, 17, 18, 19 & 20, Pharma SEZ, TICEL Bio Park Taramani, Chennai, Tamil Nadu 600113, India (Address for Par Formulations Pvt. Ltd.)
Supports Endo's global generics supply chain with R&D and manufacturing capabilities, leveraging regional expertise and cost-effectiveness for both local and international markets.
Address: First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland
Global corporate functions and strategic oversight of all Endo operations, including those related to Par Pharmaceutical.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Par Pharmaceutical' leadership includes:
Par Pharmaceutical has been backed by several prominent investors over the years, including:
Endo International underwent significant leadership and board changes as part of its financial restructuring process, which concluded with its emergence from Chapter 11 in April 2023. This involved the appointment of a new Board of Directors and affirmation of key executive leadership to guide the newly restructured private company.
Discover the tools Par Pharmaceutical uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Endo International, the parent company of Par Pharmaceutical, likely utilizes standard corporate email formats. The most common patterns are variations of [first name], [last name], and initials.
first.last@endo.com (e.g., john.doe@endo.com) OR flast@endo.com (e.g. jdoe@endo.com)
Format
john.doe@endo.com
Example
80%
Success rate
Endo International • April 26, 2023
Endo International plc announced that it has successfully completed its financial restructuring and emerged from Chapter 11 proceedings. The Company moves forward with a significantly stronger financial foundation, reduced debt, and a new, private ownership structure. Blaise Coleman will continue to lead Endo as President and CEO, and a new Board of Directors has been appointed....more
Endo International • November 16, 2023
Endo International plc announced that its Par Pharmaceutical, Inc. operating company has begun shipping dexmedetomidine hydrochloride in 0.9% sodium chloride injection, a ready-to-use formulation in a 100mL flexible container. This product is the generic equivalent of Precedex®....more
Endo International • February 29, 2024
Endo International plc announced that its Par Sterile Products business has begun shipping Vasopressin Injection, USP, 20 Units/mL, multidose vial, an authorized generic version of Par Pharmaceutical's Vasostrict®....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Par Pharmaceutical, are just a search away.